

GLAXOSMITHKLINE PLC  
Form 6-K  
February 20, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 20 February 2018

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.0000	12,482 (Deferred)
£0.0000	8,614 (Matching)
  - d) Aggregated information 21,096
  - e) Aggregated volume Price £0.0000
  - e) Date of the transaction 2018-02-16
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
- 2.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£13.1563	5,868 (Deferred)
£13.1563	4,050 (Matching)
- d) Aggregated information 9,918
- e) Aggregated volume Price £13.1563
- e) Date of the transaction 2018-02-16
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
b) Nature of the transaction	
	Price(s) Volume(s)
c) Price(s) and volume(s)	£0.0000 9,142 (Deferred) £0.0000 6,308 (Matching)
d) Aggregated information	15,450
Aggregated volume Price	£0.0000
e) Date of the transaction	2018-02-16
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr R Connor
b) Position/status	President, Global Manufacturing & Supply
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching
------------------------------	---

	Awards.
	Price(s) Volume(s)
c) Price(s) and volume(s)	£13.1028 4,384 (Deferred) £13.1200 3,026 (Matching)
d) Aggregated information	7,410
Aggregated volume Price	£13.1114
e) Date of the transaction	2018-02-16
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
------------------------------	---

	Price(s) Volume(s)
c) Price(s) and volume(s)	£0.0000 17,435 (Deferred) £0.0000 12,030 (Matching)

d) Aggregated information	29,465
Aggregated volume Price	£0.0000
e) Date of the transaction	2018-02-16
f) Place of the transaction	n/a

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr S Dingemans
  - b) Position/status Chief Financial Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882
- b) Nature of the transaction
 

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£13.1236	8,360 (Deferred)
£13.1230	5,768 (Matching)
- d) Aggregated information 14,128
- e) Aggregated volume Price £13.1233
- e) Date of the transaction 2018-02-16
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics and Compliance
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £0.0000 6,402 (Deferred)  
 £0.0000 4,418 (Matching)

d) Aggregated information 10,820  
 Aggregated volume Price £0.0000

e) Date of the transaction 2018-02-16

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics and Compliance

c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.1068 3,070 (Deferred) £13.1118 2,120 (Matching)
d) Aggregated information	5,190
e) Date of the transaction	2018-02-16
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c) Price(s) and volume(s)	Price(s) Volume(s) £0.0000 10,258 (Deferred)



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£0.0000 7,078 (Matching)

- d) Aggregated information 17,336
- d) Aggregated volume Price £0.0000
- e) Date of the transaction 2018-02-16
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£13.1800	4,822 (Deferred)
£13.1800	3,328 (Matching)

- d) Aggregated information 8,150
- d) Aggregated volume Price £13.1800
- e) Date of the transaction 2018-02-16
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882
  - b) Nature of the transaction
 

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.0000	13,805 (Deferred)
£0.0000	9,525 (Matching)
  - d) Aggregated information 23,330
  - e) Aggregated volume Price £0.0000
  - e) Date of the transaction 2018-02-16
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.1180	6,489 (Deferred)
£13.1180	4,478 (Matching)

d) Aggregated information  
Aggregated volume Price

10,967  
£13.1180

e) Date of the transaction

2018-02-16

f) Place of the transaction

London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                           |
|---------------------------------------|---------------------------|
| a) Name                               | Mr P Thomson              |
| b) Position/status                    | President, Global Affairs |
| c) Initial notification/<br>amendment | Initial Notification      |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
b) Nature of the transaction	
	Price(s) Volume(s)
c) Price(s) and volume(s)	£0.0000 4,689 (Deferred) £0.0000 3,235 (Matching)
d) Aggregated information	7,924
d) Aggregated volume Price	£0.0000
e) Date of the transaction	2018-02-19
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882

	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
b) Nature of the transaction	
	Price(s) Volume(s)
c) Price(s) and volume(s)	£13.1240 2,204 (Deferred) £13.1240 1,521 (Matching)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- d) Aggregated information 3,725
- e) Aggregated volume Price £13.1240
- e) Date of the transaction 2018-02-19
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P Vallance
- b) Position/status Outgoing President, R&D
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.0000	20,322 (Deferred)
£0.0000	14,022 (Matching)

- d) Aggregated information 34,344
- e) Aggregated volume Price £0.0000
- e) Date of the transaction 2018-02-19
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P Vallance
- b) Position/status Outgoing President, R&D
- c) Initial notification/ amendment Initial Notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction The sale of Ordinary Shares following the exercise of options on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£13.1760	20,322 (Deferred)
£13.1760	14,022 (Matching)
  - d) Aggregated information 34,344
  - e) Aggregated volume Price £13.1180
  - e) Date of the transaction 2018-02-19
  - f) Place of the transaction London Stock Exchange (XLON)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 20, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc